DOI: https://doi.org/10.30841/2307-5112.5.2018.165327

Эпидемиология, патогенез, молекулярная характеристика, классификация и прогноз диффузных В-крупноклеточных лимфом

С. М. Гайдукова, С. В. Видиборець, Ю. Ю. Попович

Аннотация


В статье приведены результаты систематического обзора литературных научных источников (поиск проведен в базах данных JAMA, Scholar, NCBI, Cochrane Library и PubMed, 2007–2018), касающихся эпидемиологии, патогенеза, молекулярных характеристик, классификации и факторов риска диффузной В-крупноклеточной лимфомы.


Ключевые слова


диффузная В-крупноклеточная лимфома; эпидемиология; патогенез; молекулярная характеристика; классификация; прогноз; факторы риска

Полный текст:

PDF (English)

Литература


Abu Shanab A.A. Salah. Modern advance for B-lymphopoiesis / Abushanab A.A. Salah // Сімейна медицина / Family medicine. – 2015. – no. 3(59). – P. 246–247.

Adams H. Diagnostic utility of the B-cell lineage markers CD20, CD79a, PAX5, and CD19 in paraffin-embedded tissues from lymphoid neoplasms / Adams H., Liebisch P., Schmid P. et al. // Appl. Immunohistochem. Mol. Morphol. – 2009. – Vol. 17. – P. 96–101. https://doi.org/10.1097/PAI.0b013e3181845ef4

Akyurek N. Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab / Akyurek N., Uner A., Benekli M. et al. // Cancer. – 2011. – Vol. 118. – P. 4173–4183. https://doi.org/10.1002/cncr.27396

A predictive model for aggressive non-Hodgkin’s lymphoma. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project // N Engl. J. Med. – 1993. – Vol. 329. – P. 987–994. https://doi.org/10.1056/NEJM199309303291402

Bakhshi A. Cloning the chromosomal breakpoint of t(14;18) human lymphomas: Clustering around JH on chromosome 14 and near a transcriptional unit on 18 / Bakhshi A. Jensen J.P., Goldman P. et al. // Cell. – 1985. – Vol. 41. – P. 899–906. https://doi.org/10.1016/S0092-8674(85)80070-2

Barrans S. Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab / Barrans S. Crouch S., Smith A. et al. // J Clin. Oncol. – 2010. – Vol. 28. – P. 3360–3365. https://doi.org/10.1200/JCO.2009.26.3947

Bergsagel P.L. Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma / Bergsagel P.L. Chesi M., Nardini E. et al. // Proc Natl. Acad. Sci. U.S.A. – 1996. – Vol. 93. – P. 13931–13936. https://doi.org/10.1073/pnas.93.24.13931

Campo E. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications / Campo E., Swerdlow SH., Harris NL. et al. // Blood. – 2011. – Vol. 117. – P. 5019–5032. https://doi.org/10.1182/blood-2011-01-293050

Choi W.W. A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy / Choi W.W., Weisenburger D.D., Greiner T.C. et al. // Clin. Cancer. Res. – 2009. – Vol. 15. – P. 5494–5502. https://doi.org/10.1158/1078-0432.CCR-09-0113

Colleoni G.W. Linfomas não-hodgkin: aspectos clínicos, prognósticos e terapêuticos na era do rituximabe / Colleoni G.W., Inaoka R.J. // Diálogo Científico. – 2007. – Vol. (Nov/Dec). – P. 19–22.

Compagno M. Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma / Compagno M., Lim W.K., Grunn A. et al. // Nature. – 2009. – Vol. 459. – P. 717–721. https://doi.org/10.1038/nature07968

Davis R.E. Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells / Davis RE., Brown KD., Siebenlist U. et al. // J Exp. Med. – 2001. – Vol. 194. – P. 1861–1874. https://doi.org/10.1084/jem.194.12.1861

Davis R.E. Chronic active B-cellreceptor signalling in diffuse large B-cell lymphoma / Davis R.E., Ngo VN., Lenz G. et al. // Nature. – 2010. – Vol. 463. – P. 88–92. https://doi.org/10.1038/nature08638

Friedberg J.W. Rituximab for early stage diffuse large B-cell lymphoma // Lancet Oncol. – 2006. – Vol. 7 (5). – P. 357–359. https://doi.org/10.1016/S1470-2045(06)70668-4

Fugmann S.D. The RAG proteins and V(D)J recombination: Complexes, ends, and transposition / Fugmann S.D., Lee A.I., Shockett P.E. et al. // Annu. Rev. Immunol. – 2000. – Vol. 18. – P. 495–527. https://doi.org/10.1146/annurev.immunol.18.1.495

Gomez-Abad C. PIM inhibition as a rational therapeutic approach in diffuse large B cell lymphoma / Gomez-Abad C., Pisonero H., Blanco-Aparicio C. // Ann. Oncol. – 2011. – Vol. 22. Abstract 154. https://doi.org/10.1093/annonc/mdr211

Gonçalves E.M. Linfomas difusos de grandes células B – factores de prognóstico clínicos [dissertation] // Porto: Universidade do Porto. – 1999. PDF

Goossens T. Frequent occurrence of deletions and duplications during somatic hypermutation: Implications for oncogene translocations and heavy chain disease / Goossens T., Klein U., Kuppers R. // Proc Natl Acad Sci USA. – 1998. – Vol. 95. – P. 2463–2468. https://doi.org/10.1073/pnas.95.5.2463

Hans C.P. Confirmation of the molecular classification of diffuse large Bcell lymphoma by immunohistochemistry using a tissue microarray / Hans C.P., Weisenburger D.D., Greiner T.C. et al. // Blood. – 2004. – Vol. 103. – P. 275–282. https://doi.org/10.1182/blood-2003-05-1545

Hill B.T. Cell of origin determination in diffuse large b-cell lymphoma: Performance of immunohistochemical (IHC) algorithms and ability to predict outcome / Hill B.T., Collie A.M.B., Radivoyevitch T. et al. // Blood. – 2011. – Vol. 118 (suppl 21):Abstract. 950. Full text

Iqbal J. BCL2 predicts survival in germinal center B-cell-like diffuse large B-cell lymphoma treated with CHOP-like therapy and rituximab / Iqbal J., Meyer P.N., Smith L.M. et al. // Clin. Cancer Res. – 2011. – Vol. 17. – P. 7785–7795. https://doi.org/10.1158/1078-0432.CCR-11-0267

Joos S. Primary mediastinal (thymic) B-cell lymphoma is characterized by gains of chromosomal material including 9p and amplification of the REL gene / Joos S., Otano-Joos M.I., Ziegler S. et al. // Blood. – 1996. – Vol. 87. – P. 1571–1578. PDF

Kato M. Frequent inactivation of A20 in B-cell lymphomas / Kato M., Sanada M., Kato I. et al. // Nature. – 2009. – Vol. 459. – P. 712–716. https://doi.org/10.1038/nature07969

Klapper W. Structural aberrations affecting the MYC locus indicate a poor prognosis independent of clinical risk factors in diffuse large B-cell lymphomas treated within randomized trials of the German High-Grade Non-Hodgkin’s Lymphoma Study Group (DSHNHL) / Klapper W., Stoecklein H., Zeynalova S. et al. // Leukemia. – 2008. – Vol. 22. – P. 2226–2229. https://doi.org/10.1038/leu.2008.230

Kraus M. Survival of resting mature B lymphocytes depends on BCR signaling via the Igalpha/beta heterodimer / Kraus M., Alimzhanov M.B., Rajewsky N. et al. // Cell. – 2004. –Vol. 117. – P. 787–800. https://doi.org/10.1016/j.cell.2004.05.014

Lam L.T. Small molecule inhibitors of I kappa B kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling / Lam L.T., Davis R.E, Pierce J. et al. // Clin. Cancer Res. – 2005. – Vol. 11. – P. 28–40.

Lam L.T. Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-{kappa}B pathways in subtypes of diffuse large B-cell lymphoma / Lam L.T., Wright G., Davis R.E. et al. // Blood. – 2008. – Vol. 111. – P. 3701–3713. https://doi.org/10.1182/blood-2007-09-111948

Lenz G. Aggressive lymphomas / Lenz G., Staudt L.M. // N. Engl. J. Med. – 2010. – Vol. 362. – P. 1417–1429. https://doi.org/10.1056/NEJMra0807082

Liu M. Two levels of protection for the B cell genome during somatic hypermutation / Liu M., Duke J.L., Richter D.J. et al. // Nature. – 2008. – Vol. 451. – P. 841–845. https://doi.org/10.1038/nature06547

Lohr J.G. Discovery and prioritization of somatic mutations in diffuse large Bcell lymphoma (DLBCL) by whole-exome sequencing / Lohr J.G., Stojanov P., Lawrence M.S. et al. // Proc. Natl. Acad. Sci. U.S.A. – 2012. – Vol. 109. – P. 3879–3884. https://doi.org/10.1073/pnas.1121343109

Lymphomas 2018. ESMO Pocket Guidelines. European Society by Medical Oncology, 191 p.

Manis J. P. Mechanism and control of class-switch recombination / Manis J.P., Tian M., Alt F.W. // Trends Immunol. – 2002. – Vol. 23. – P. 31–39. https://doi.org/10.1016/S1471-4906(01)02111-1

Meyer P.N. Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large Bcell lymphoma treated with rituximab. / Meyer P.N., Fu K., Greiner T.C. et al. // J. Clin. Oncol. – 2011. – Vol. 29. – P. 200–207. https://doi.org/10.1200/JCO.2010.30.0368

Migliazza A. Frequent somatic hypermutation of the 5-noncoding region of the BCL6 gene in B-cell lymphoma / Migliazza A., Martinotti S., Chen W. et al. // Proc. Natl. Acad. Sci. U. S. A. – 1995. – Vol. 92. – P. 12520–12524. https://doi.org/10.1073/pnas.92.26.12520

Morin R.D. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma / Morin R.D., Mendez-Lago M., Mungall A.J. et al. // Nature. – 2011. – Vol. 476. – P. 298–303. https://doi.org/10.1038/nature10351

Muramatsu M. Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme / Muramatsu M., Kinoshita K., Fagarasan S. et al // Cell. – 2000. – Vol. 102. – P. 553–563. https://doi.org/10.1016/S0092-8674(00)00078-7

Nardini E. Detection of aberrant isotype switch recombination in low-grade and high-grade gastric MALT lymphomas / Nardini E., Aiello A., Giardini R. et al. // Blood. – 2000. – Vol. 95. – P. 1032–1038. PDF

Ngo V.N. A loss-of-function RNA interference screen for molecular targets in cancer / Ngo V.N., Davis R.E., Lamy L. et al. // Nature. – 2006. – Vol. 441. – P. 106–110. https://doi.org/10.1038/nature04687

Nogai H. Pathogenesis of Non-Hodgkin’s Lymphoma / Nogai H., Dorken B., Lenz G. // J. Clin. Oncol. – 2011. – Vol. 29. – P. 1803–1811. https://doi.org/10.1200/JCO.2010.33.3252

Obermann E.C. BCL2 gene aberration as an IPI-independent marker for poor outcome in non-germinal-centre diffuse large B cell lymphoma / Obermann E.C., Csato M., Dirnhofer S. et al. // J. Clin. Pathol. – 2009. – Vol. 62. – P. 903–907. https://doi.org/10.1136/jcp.2009.066597

Ott M.M. The Hans classificator does not predict outcome in diffuse large B cell lymphoma in a large multicenter retrospective analysis of R-CHOP treated patients / Ott M.M., Horn H., Kaufmann M. et al. // Leuk Res. – 2012. – Vol. 36. – P. 544–545. https://doi.org/10.1016/j.leukres.2012.01.022

Ott G. Immunoblastic morphology but not the immunohistochemical GCB / nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL / Ott G., Ziepert M., Klapper W. et al. // Blood. – 2010. – Vol. 116. – P. 4916–4925. https://doi.org/10.1182/blood-2010-03-276766

Pasqualucci L. Inactivating mutations of acetyltransferase genes in B-cell lymphoma / Pasqualucci L., Dominguez-Sola D., Chiarenza A. et al. // Nature. – 2011. – Vol. 471. – P. 189–195. https://dx.doi.org/10.1038%2Fnature09730

Pasqualucci L. Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas / Pasqualucci L., Neumeister P., Goossens T. et al. // Nature. – 2001. – Vol. 412. – P. 341–346. https://doi.org/10.1038/35085588

Pasqualucci L. Analysis of the coding genome of diffuse large B-cell lymphoma / Pasqualucci L., Trifonov V., Fabbri G. et al. // Nat Genet. – 2011. – Vol. 43. – P. 830–837. https://doi.org/10.1038/ng.892

Pui C.H. Central nervous system disease in hematologic malignancies: historical perspective and practical applications / C.H. Pui, E. Thiel // Semin. Oncol. – 2009. – Vol. 36. – P. S2–S16. https://doi.org/10.1053/j.seminoncol.2009.05.002

Rajewsky K. Clonal selection and learning in the antibody system // Nature. – 1996. – Vol. 381. – P. 751–758. https://doi.org/10.1038/381751a0

Ramiro A.R. AID is required for cmyc/IgH chromosome translocations in vivo / Ramiro A.R., Jankovic M., Eisenreich T. et al. // Cell. – 2004. – Vol. 118. – P. 431–438. https://doi.org/10.1016/j.cell.2004.08.006

Ryan R.J. EZH2 codon 641 mutations are common in BCL2-rearranged germinal center B cell lymphomas / Ryan R.J., Nitta M., Borger D. et al. // PLoS One. – 2011. – Vol. 6:e28585. https://doi.org/10.1371/journal.pone.0028585

Rosenwald A. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma / Rosenwald A., Wright G., Chan W.C. et al. // N. Engl. J. Med. –2002. – Vol. 346. – P. 1937–1947. https://doi.org/10.1056/NEJMoa012914

Rosenwald A. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma / Rosenwald A., Wright G., Leroy K. et al. // J. Exp. Med. – 2003. – Vol. 198. – P. 851–862. https://doi.org/10.1084/jem.20031074

Salah A.A. Abushanab. Analysis of Tp53 gene polymorphic variants in predicting of toxic complication in non-Hodgkin’s lymphoma treatment / Salah A.A. Abushanab, Vydyborets S., Gorovenko N., Gartovska I., Kyriachenko S., Rossokha Z. // Hematology. Transfusiology. Eastern Europe. – 2016. – Vol. 2, no. 1. – P. 155–165.

Salah A.A. Abushanab. Evaluation of clinic and laboratory parameters and genetic markers in predicting of toxic complications in treatment of patients with non-Hodgkin’s lymphoma / Salah A.A. Abushanab, Vydyborets S., Gorovenko N., Gartovska I., Kyriachenko S., Rossokha Z. // Hematology. Transfusiology. Eastern Europe. – 2016. – Vol. 2, no. 2. – P. 198–206.

Salah A.A. Abushanab. The influence of genetic factors on the development of different clinical manifestations of toxicity in patients with non-Hodgkin’s lymphoma / Salah A.A. Abushanab, Vydyborets S., Gorovenko N., Gartovska I., Kyriachenko S., Rossokha Z. // Hematology. Transfusiology. Eastern Europe. – 2015. –no. 3 (03). – P. 48–61.

Schmitz R. TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma / Schmitz R., Hansmann ML., Bohle V. et al. // J. Exp. Med. – 2009. – Vol. 206. – P. 981–989. https://doi.org/10.1084/jem.20090528

Shahi P.K. Linfoma B difuso de células grandes / Shahi P.K., Manga G.P. // Med. Clin. (Barc). – 2006. – Vol. 127 (1). – P. 17–21. https://doi.org/10.1157/13089865

Song M.K. Prognostic significance of the Bcl-2 negative germinal centre in patients with diffuse large B cell lymphoma treated with R-CHOP / Song M.K., Chung J.S., Shin D.H. et al. // Leuk. Lymphoma. – 2009. – Vol. 50. – P. 54–61. https://doi.org/10.1080/10428190802626616

Swerdlow S.H. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue (IARC WHO Classification of Tumours). // World Health Organization. – 2008. – 4th edition.

Thieblemont C. The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: A bio-CORAL study / Thieblemont C., Briere J., Mounier N. et al. // J. Clin. Oncol. – 2011. – Vol. 29. – P. 4079–4087. https://doi.org/10.1200/JCO.2011.35.4423

Turner J.J. WHO non-Hodgkin’s lymphoma classification by criterionbased report review followed by targeted pathology review: an effective strategy for epidemiology studies / Turner J.J., Hughes A.M., Kricker A. et al. // Cancer Epidemiol. Biomarkers Prev. – 2005. – Vol. 14. – P. 2213–2219. https://doi.org/10.1158/1055-9965.EPI-05-0358

Tzankov A. Prognostic immunophenotypic biomarker studies in diffuse large B cell lymphoma with special emphasis on rational determination of cut-off scores. / Tzankov A., Zlobec I., Went P. et al. // Leuk. Lymphoma. – 2010. – Vol. 51. – P. 199–212. https://doi.org/10.3109/10428190903370338

Visco C. The t(14;18)(q32;q21) characterizes a subset of patients with diffuse large-B cell lymphoma of germinal center origin with poor outcome: Report from the international DLBCL rituximab-CHOP consortium program study / Visco C., Tzankov A., Xu-Monette Z.Y. et al. // Blood. – 2011. – Vol. 118. – Abstract 949. Full text

Wang X. Negative autoregulation of BCL-6 is bypassed by genetic alterations in diffuse large B cell lymphomas / Wang X., Li Z., Naganuma A. et al. // Proc. Natl. Acad. Sci. USA. – 2002. – Vol. 99. – P. 15018–15023. https://doi.org/10.1073/pnas.232581199

World Health Organization. Pathology and genetics of tumours of haematopoietic and lymphoid tissues // Lyon: International Agency for Research on Cancer. 2001.




Copyright (c) 2018 Семейная медицина

Creative Commons License
Эта работа лицензирована Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

ISSN 2412-8708 (Online), ISSN 2307-5112 (Print)

Flag Counter